Carisma Q2 net loss $19.9M, cash $117.1M; dosed first patient in CT-0508+KEYTRUDA combo trial

Carisma Therapeutics Inc.

2023-Q2 EPS reported -$1.67 revenue$6,803,000

Dosed first patient in Phase 1 trial of CT-0508 in combination with KEYTRUDA for HER2-overexpressing solid tumors.
Nominated additional oncology target under Moderna collaboration; total of five nominated targets.
Cash, cash equivalents and marketable securities $117.1M as of June 30, 2023 (down from $139.0M Q1 2023); expected to fund through end of 2024.
Net loss $19.9M for Q2 2023 vs $14.8M for Q2 2022; R&D expenses increased to $18.5M from $14.2M.
Appointed Eric Siegel as General Counsel and Terry Shields as SVP of Human Resources.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Carisma Therapeutics Inc. reported the quarter ended June 30, 2023 results: net income Net loss was $19.9 million for the second quarter of 2023.

Period: the quarter ended June 30, 2023
Net income: Net loss was $19.9 million for the second quarter of 2023
Result: reported results

Exact text from the filing

Carisma Therapeutics Inc. (the “Company”) announced its financial results for the quarter ended June 30, 2023.

View on SEC.gov

Browse all earnings releases →

Carisma Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-089563

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.